



Bridging Science and Sight:

A Journey Through Retinal Research

Murtaza Adam, MD, FASRS

Financial Disclosures



Murtaza Adam, MD

The content and format of this course is presented without commercial bias and does not claim superiority of any commercial product or service.

- ▶ **Consultant:** Genentech/Roche, Regeneron, Abbvie, Apellis, Iveric Bio (an Astellas Company), Northgauge Healthcare Advisors, Alkeus, Neurotech, 4DMT, Dutch Ophthalmic Research Center, Harrow
- ▶ **Speaker:** Genentech/Roche, Regeneron, Iveric Bio (an Astellas Company), Apellis, Amgen
- ▶ **Research Support:** Genentech/Roche, Regeneron, EyeBio, Abbvie, Regenxbio, EyePoint, 4DMT, Apellis
- ▶ **Advisory Board:** Lumata Health, Sanro Health
- ▶ **Investor:** Lumata Health, Sanro Health

Clinical Research @ Colorado Retina



- About Us
- Our Providers
- Retinal Care
- Subspecialty Care
- Research
- Patient Support

Research



Home > Research

About Our Research Program

Our FDA-backed, clinical research program is a vital part of improving our patients' well-being. We have participated in hundreds of innovative trials surrounding a variety of retinal

Research

- About Our Research
- Clinical Trials






The path to approval...

THE BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT PROCESS

From drug discovery through FDA approval, developing a new medicine takes at least 10 years on average and costs an average of \$2.6 billion.* Less than 12% of the candidate medicines that make it into Phase I clinical trials will be approved by the FDA.



Pearls

Key Take-Aways

- 1. Only approximately 10% of potential medications that undergo Phase I clinical trial testing ultimately achieve FDA approval.**
- 2. There are many barriers to patients enrolling in a clinical trial, but many of those patients that make it in one often want to do another.**
- 3. A combination of oversight, ethical principles, cutting edge science, and commitment from our patients is what makes clinical research successful.**

“When I was diagnosed with AMD ten years ago, there was no treatment for dry AMD except 'take AREDS twice a day, every day.’

I believe that I started the injections in June of 2023 - which was shortly after the FDA approved it.

I would like to emphasize that fact, as the diagnosis was devastating to me. I made a living from my eyes. You gave me hope, and continue to do so for all of us with this condition.”



Thank you!

UP NEXT: Retinal Manifestations of Alzheimer's Disease

Guest Speaker: Victoria Pelak, MD, Neuro-ophthalmologist